Home Clinical Topics Medications

Medications

New treatment for acute hepatic porphyria

The U.S. Food and Drug Administration (FDA) recently granted approval to Alnylam Pharmaceuticals’ givosiran (Givlaari), a new treatment for adult patients with acute hepatic porphyria (AHP).    AHP is a genetic disorder that manifests as a “buildup of toxic porphyrin molecules” that form “during the...

Study reveals no link between statin use and cognitive decline

A new study offers insight into a question that’s plagued healthcare for some time: Does an association exist between statin use and cognitive decline? A team from the Garvan Institute of Medical Research and the University of...

Legalized recreational marijuana may increase risk for cannabis use disorder

A recent study from JAMA Psychiatry examines this question: Has legalization of recreational marijuana in the United States affected the rates of cannabis use disorder (CUD)? The research was conducted through a repeated, cross-sectional, self-reported...

Accelerated approval for a new mantle cell lymphoma drug

The Food and Drug Administration (FDA) has recently granted accelerated approval to BeiGene’s mantle cell lymphoma (MCL) oral therapy, zanubritinib (BRUKINSA). Zanubritinib’s efficacy was examined through a phase 2 clinical trial (BGB-311-206 / NCT0306970) in...

Johns Hopkins Center for Psychedelic Research

In early September 2019, Johns Hopkins opened its new Center for Psychedelic and Consciousness Research, which explores the use of psychedelics on brain function, memory, and the brain’s biology. The center explores the use of...

A new technology may better help control type 1 diabetes

A recent study from The New England Journal of Medicine (NEJM) reveals a new system that has “improved glycemic outcomes in patients with type 1 diabetes.” The technology in question is a closed-loop system...

Potential new treatment for peanut allergies

Aimmune Therapeutics is set to present new data on its AR101 compound, Palforzia, a potential new treatment for peanut allergies, in early November 2019 at the American College of Asthma, Allergy, and Immunology (ACAAI)...

Medical Cannabis: What Nurses Need to Know

Nurses can help patients make smart decisions by educating themselves. Takeaways: Nurses frequently treat patients who use or are considering using cannabis as a medicine. Finding and validating information can be challenging, but proper and...

Antibiotic stewardship

Every nurse has a responsibility to prevent antibiotic resistance. Takeaways: Nurses have a key role to play in preventing infections and preserving the power of antibiotics. Antimicrobial resistance is a growing danger that threatens our...

Potential new treatment for atopic dermatitis

Eczema is a common ailment for many people, but a more severe type of eczema not as well-known, atopic dermatitis (AD), may have a new treatment option available. AD is a more severe manifestation of...

Emerging treatment for early Alzheimer’s disease

Biogen announced that it will pursue the U.S. Food and Drug Administration (FDA)’s regulatory approval process for its drug aducanumab to treat Alzheimer’s disease. The decision was based on findings from the phase 4 EMERGE...

New FDA guidelines on risks of smokeless tobacco products

For the first time ever, the U.S. Food and Drug Administration (FDA) has authorized eight Swedish Match USA, Inc. snus smokeless tobacco products to be marketed through the modified risk tobacco product (MRTP) pathway. Recently,...

New treatment for cystic fibrosis

The U.S. Food and Drug Administration has approved a new “breakthrough therapy” for cystic fibrosis (CF) in late October 2019. The new drug is Vertex Pharmaceutical’s Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triplet combination therapy for patients...